Alveus Therapeutics’ Phase 2-ready lead drug hits the same two targets as Amgen’s MariTide, but with the potential for a dosing advantage. The startup’s pipeline also includes molecules that could compete with drugs in development by Roche and Novo Nordisk.
The post Startup Alveus Therapeutics Emerges With $160M to Shape the Future of Obesity Drugs appeared first on MedCity News.
